Document is current

Article History

Received: 19 May 2025

Accepted: 15 August 2025

First Online: 29 August 2025

Declarations

:

: HC.P. has received travel support from Eli Lilly, MSD, Novartis, Pfizer, Pierre Fabre and Roche and received lecture honoraria from Eli Lilly. A.I-M.: Participation in advisory boards organized by MSD, Servier, Daiichi Sankyo and BMS, Lecture honoraria from Eli Lilly, Servier, BMS, MSD, Astellas and Daiichi Sankyo, Local PI for clinical trials sponsored by BMS and Roche, Consulting for Astellas and MSD, Travel support from BMS, Roche, Eli Lilly and Daiichi Sankyo. M.P. has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Servier. AS.B. has research support from Daiichi Sankyo and Roche, honoraria for lectures, consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, Daiichi Sankyo; as well as travel support from Roche, Amgen, Daiichi Sankyo, and AbbVie.GW.P. has the following to declare: Advisory Role/Speaker's Fee: Merck Serono, Roche, Amgen, Sanofi, Lilly, Servier, Taiho, Bayer, Halozyme, BMS, MSD, Celgene, Pierre Fabre, Shire, CECOG, Astra Zeneca. All other authors declare no conflict of interest.

: All procedures were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1964 and later versions. The study was approved by the ethics committee of the Medical University of Vienna (reference number: 1600/2021). The risk of publication of sensitive patient data was minimized by restrictions of data accession and pseudonymized statistical analysis.

: Due to the retrospective design no separate informed consent was necessary in the scope of this study. This is in line with local ethical standards and was approved by the ethics committee of the Medical University of Vienna (reference number: 1600/2021).